Head-to-head evidence
CT-P10 vs PF-05280586
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: CD20 · full Rheumatoid Arthritis pipeline
CT-P10
Developed by Celltrion
NCT02149121 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial with an adequately sized population (384 enrolled) that pre-specified formal equivalence margins for both its pharmacokinetic and its clinical disease-activity (DAS28-CRP) primary endpoints, and every comparison landed entirely within the required margin, meaning the biosimilar demonstrated therapeutic equivalence to the reference product on a validated hard clinical measure of rheumatoid arthritis activity, not just a proxy lab value.
PF-05280586
Marketed by Pfizer
NCT01526057 · Phase 2 · completed
The 220-participant trial was randomized, quadruple-blind, and actively controlled with European- and US-sourced rituximab. The primary pharmacokinetic comparisons met the prespecified equivalence range for both peak concentration and total drug exposure, but these were surrogate measures rather than hard clinical outcomes, supporting a moderate evidence grade.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CT-P10's landscape · PF-05280586's landscape